Drug Trial Radar · NCT06859268
A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity
Last checked: Nov 20, 2026Latest source record: Mar 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
643
Planned (sponsor's estimate)
Start
Mar 5, 2025
Primary completion
Apr 2028
Study completion Apr 2028
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Mar 5, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study of retatrutide in participants with obesity. The main purpose is to learn more about how retatrutide maintains body weight loss. The study will have two treatment phases: an 80 week lead-in phase in which all participants will take retatrutide dose 1 and a 36 week randomized, double-blinded phase in which participants will either take retatrutide dose 1, retatrutide dose 2, or switch to placebo. Participation in the study will last around 125 weeks.
Conditions
- Obesity
Interventions
RetatrutideDrug
Administered SC
PlaceboDrug
Administered SC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change from Baseline in Body WeightTime frame: Week 0, Week 116
Locations
53 sites in 3 countries. Site status is shown where the registry gives one.
Southern California Clinical Research
Santa Ana, California
University of Colorado Anschutz Medical Campus
Aurora, Colorado
CMR of Greater New Haven, LLC
Hamden, Connecticut
ALL Medical Research, LLC
Cooper City, Florida
Florida International Medical Research
Coral Gables, Florida
Renstar Medical Research
Ocala, Florida
Charter Research - Winter Park
Orlando, Florida
Metabolic Research Institute, Inc.
West Palm Beach, Florida
Kubost Clinical Research - Marietta
Marietta, Georgia
North Georgia Clinical Research
Woodstock, Georgia
Pacific Diabetes & Endocrine Center
Honolulu, Hawaii
Alliance for Multispecialty Research, LLC
Oak Brook, Illinois
Springfield Clinic Main Campus
Springfield, Illinois
Alliance for Multispecialty Research, LLC
Lexington, Kentucky
L-MARC Research Center
Louisville, Kentucky
Pennington Biomedical Research Center
Baton Rouge, Louisiana
Care Access - Lake Charles (Bayou Pines)
Lake Charles, Louisiana
Massachusetts General Hospital
Boston, Massachusetts
Alliance for Multispecialty Research, LLC
Kansas City, Missouri
Vector Clinical Trials
Las Vegas, Nevada
Dent Neurosciences Research Center, Inc
Amherst, New York
Carteret Medical Group
Morehead City, North Carolina
Care Access - Raleigh
Raleigh, North Carolina
Tekton Research, LLC.
Moore, Oklahoma
Altoona Center For Clinical Research
Duncansville, Pennsylvania
Care Access - Rapid City
Rapid City, South Dakota
Alliance for Multispecialty Research, LLC
Knoxville, Tennessee
Care Access - Houston
Houston, Texas
Southern Endocrinology Associates
Mesquite, Texas
Sleep Therapy Research Center
San Antonio, Texas
National Clinical Research, Inc
Richmond, Virginia
Northwest Clinical Research Center
Bellevue, Washington
Central Washington Health Services Association d/b/a Confluence Health
Wenatchee, Washington
Aggarwal and Associates Limited
Brampton, Canada
Circulate Cardiac & Vascular Centre
Burlington, Canada
Med Trust Research
Courtice, Canada
Winterberry Research Inc.
Hamilton, Canada
Centre de Medecine Metabolique de Lanaudiere (CMML)
Terrebonne, Canada
Care Access - Thunder Bay - Barton Street
Thunder Bay, Canada
Maple Leaf Research
Toronto, Canada
Showing 40 of 53 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.